<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">J Vasc Surg</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of vascular surgery</journal-title></journal-title-group><issn pub-type="ppub">0741-5214</issn><issn pub-type="epub">1097-6809</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10699768</article-id><article-id pub-id-type="pmcid-ver">PMC10699768.319</article-id><article-id pub-id-type="pmcaid">10699768</article-id><article-id pub-id-type="pmcaiid">10699768</article-id><article-id pub-id-type="manuscript-id">NIHMS1945908</article-id><article-id pub-id-type="pmid">37141948</article-id><article-id pub-id-type="doi">10.1016/j.jvs.2023.04.032</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1945908</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1945908</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Market Competition Influences Practice Patterns in Management of Patients with Intermittent Claudication in the Vascular Quality Initiative</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Weaver</surname><given-names initials="ML">M. Libby</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neal</surname><given-names initials="D">Dan</given-names></name><degrees>MS</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Columbo</surname><given-names initials="JA">Jesse A</given-names></name><degrees>MD, MS</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holscher</surname><given-names initials="CM">Courtenay M</given-names></name><degrees>MD, PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sorber</surname><given-names initials="RA">Rebecca A</given-names></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hicks</surname><given-names initials="CW">Caitlin W</given-names></name><degrees>MD, MS</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stone</surname><given-names initials="DH">David H</given-names></name><degrees>MD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clouse</surname><given-names initials="WD">W. Darrin</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Scali</surname><given-names initials="ST">Salvatore T</given-names></name><degrees>MD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Vascular and Endovascular Surgery, University of Virginia Health System, Charlottesville, VA</aff><aff id="A2"><label>2</label>Department of Surgery, University of Florida, Gainesville, FL</aff><aff id="A3"><label>3</label>Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH</aff><aff id="A4"><label>4</label>Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, Baltimore, MD</aff><aff id="A5"><label>5</label>Division of Vascular Surgery and Endovascular Therapy, University of Florida, Gainesville, FL</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> M. Libby Weaver, MD, 1215 Lee Street, PO Box 800679, Charlottesville, VA 22908-0679, <email>libbyweaver@virginia.edu</email>, Phone: (434) 243-2000</corresp><fn fn-type="COI-statement" id="FN2"><p id="P37"><bold>Disclosures:</bold> No competing interests declared. This work was completed without financial support.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>02</day><month>5</month><year>2023</year></pub-date><volume>78</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">450407</issue-id><fpage>727</fpage><lpage>736.e3</lpage><pub-history><event event-type="nihms-submitted"><date><day>30</day><month>11</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-05 09:25:41.230"><day>05</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1945908.pdf"/><abstract id="ABS1"><sec id="S1"><title>OBJECTIVES:</title><p id="P1">The Society for Vascular Surgery (SVS) clinical practice guidelines recommend best medical therapy(BMT) as first-line therapy before offering revascularization to patients with intermittent claudication(IC). Notably, atherectomy and tibial-level interventions are generally discouraged for management of IC; however, high regional market competition may incentivize physicians to treat patients outside the scope of guideline-directed therapy. Therefore, we sought to determine the association between regional market competition and endovascular treatment of patients with IC.</p></sec><sec id="S2"><title>METHODS:</title><p id="P2">We examined IC patients undergoing index endovascular peripheral vascular interventions(PVI) in the SVS-VQI from 2010&#8211;2022. We assigned the Herfindahl-Hirschman Index(HHI) as a measure of regional market competition and stratified centers into very high competition(VHC), high competition(HC), moderate competition(MC), and low competition(LC) cohorts. We defined BMT as preoperative documentation of being on antiplatelet medication, statin, non-smoking status, and a recorded ankle-brachial index. We used logistic regression to evaluate the association of market competition with patient and procedural characteristics. A sensitivity analysis was performed in patients with isolated femoropopliteal disease matched by the TransAtlantic InterSociety(TASC) classification of disease severity.</p></sec><sec id="S3"><title>RESULTS:</title><p id="P3">24,669 PVIs met inclusion criteria. IC patients undergoing PVI were more likely to be on BMT when treated in higher market competition centers(OR 1.07 per increase in competition quartile, 95% CI 1.04&#8211;1.11;p&lt;0.0001). The probability of undergoing aortoiliac interventions decreased with increasing competition(OR 0.84, 0.81&#8211;0.87;p&lt;0.0001), but there were higher odds of receiving tibial(OR 1.40, 1.30&#8211;1.50; p&lt;0.0001) and multi-level interventions in VHC vs. LC centers(femoral+tibial OR 1.10, 1.03&#8211;1.14;p=.001). Stenting decreased as competition increased(OR 0.89, 0.87&#8211;0.92;p&lt;.0001), while exposure to atherectomy increased with higher market competition(OR 1.15, 1.11&#8211;1.19; p&lt;.0001). When assessing patients undergoing single-artery femoropopliteal intervention for TASC A or B lesions to account for disease severity, the odds of receiving either balloon angioplasty(OR 0.72, .625&#8211;.840;p&lt;.0001) or stenting only(OR 0.84, .727&#8211;.966;p&lt;.0001) were lower in VHC centers. Similarly, the likelihood of receiving atherectomy remained significantly higher in VHC centers(OR 1.6, 1.36&#8211;1.84;p&lt;.0001).</p></sec><sec id="S4"><title>CONCLUSIONS:</title><p id="P4">High market competition was associated with moreprocedures among patients with claudication that are not consistent with guideline-directed therapy per the SVS clinical practice guidelines, including atherectomy and tibial-level interventions. This analysis demonstrates the susceptibility of care delivery to regional market competition and signifies a novel and undefined driver of PVI variation among patients with claudication.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Table of Contents Summary</title><p id="P5">In this retrospective analysis of index peripheral vascular interventions in patients with intermittent claudication from the SVS-VQI registry, increasing regional market competition was associated with more aggressive surgical revascularization strategies including higher likelihood of undergoing tibial-level interventions and atherectomy. Identifying factors and developing quality improvement incentives that influence market-driven physician practice patterns in the management of patients with claudication may improve appropriateness of healthcare delivery in this population.</p></abstract><kwd-group><kwd>Intermittent claudication</kwd><kwd>peripheral artery disease</kwd><kwd>peripheral vascular interventions</kwd><kwd>endovascular surgery</kwd><kwd>clinical guidelines</kwd><kwd>market competition</kwd><kwd>Vascular Quality Initiative</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>